Francisco Javier Bautista-Paloma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Francisco Javier Bautista-Paloma has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Bernardo Santos-Ramos
Servicio de Farmacia, Hospital Universitario Virgen del Rocío, E-41013 Seville, Spain
3 shared publications - Mercedes Galván-Banqueri
Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío, Sevilla, España
3 shared publications A. Candela
2 shared publicationsA. Castillo-Muñoz
2 shared publicationsA. García de Lorenzo
2 shared publicationsA. Gómez-Luque
2 shared publications
Latest Publications
- 16 October 2015
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 38 (1) , 70-79
Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa
Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa. Setting Multicenter clinical trial with 11 third level Spanish hospitals. Method Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II). Main outcome measure Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported. Conclusion Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.
- 16 October 2015
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 38 (1) , 70-79
Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa
Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa. Setting Multicenter clinical trial with 11 third level Spanish hospitals. Method Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II). Main outcome measure Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported. Conclusion Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.
- 4 March 2014
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 36 (3) , 476-487
Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer
Introduction Lung cancer accounts for 20 % of cancer deaths in Spain. The most frequent subtype (87 %) is non-small cell lung cancer (NSCLC). Pemetrexed is a recently marketed drug added to NSCLC therapeutic arsenal. It seems to have become one of the most used options for the treatment of this condition over the last 3 years. Aim of the review To evaluate the efficacy and safety of pemetrexed in NSCLC, in the different therapy lines. Method A systematic search of published literature was conducted using the main databases (MEDLINE, EMBASE, the Cochrane Library and the Center for Reviews and Dissemination) and subsequently a search of referenced literature was performed. We included clinical trials, meta-analyses and systematic reviews. The evaluation of the quality of the articles was performed by pairs using specific assessment scales, Critical Appraisal Skills Program (CASP) adapted for CASP Spain. Then we extracted data on efficacy and safety according to the treatment line assessed. Results We identified 277 references. Finally, nine clinical trials and a meta-analysis complied with inclusion criteria. In first-line induction, treatment with pemetrexed associated with a platinum was similar in terms of efficacy to other alternative chemotherapy regimens, except in patients with non-squamous histology, in whom survival was higher in the experimental group. In maintenance treatment, greater efficacy was seen with pemetrexed in patients with non-squamous histology. In second-line treatment, there were no significant differences in terms of efficacy and safety for pemetrexed treatment versus other chemotherapy options. The most frequent adverse reactions were: hematological, gastrointestinal and neurological. All were significantly less frequent with pemetrexed versus other alternative therapies, except for liver toxicity. Conclusions Due to the high degree of uncertainty as to its efficacy in certain subgroups of patients, including conflicting data; to its recent incorporation, and therefore lack of safety data in the medium and long term, and the high budgetary impact of its incorporation into health systems, it seems reasonable to optimize its use, identifying those patients who may benefit most.
- 4 March 2014
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 36 (3) , 476-487
Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer
Introduction Lung cancer accounts for 20 % of cancer deaths in Spain. The most frequent subtype (87 %) is non-small cell lung cancer (NSCLC). Pemetrexed is a recently marketed drug added to NSCLC therapeutic arsenal. It seems to have become one of the most used options for the treatment of this condition over the last 3 years. Aim of the review To evaluate the efficacy and safety of pemetrexed in NSCLC, in the different therapy lines. Method A systematic search of published literature was conducted using the main databases (MEDLINE, EMBASE, the Cochrane Library and the Center for Reviews and Dissemination) and subsequently a search of referenced literature was performed. We included clinical trials, meta-analyses and systematic reviews. The evaluation of the quality of the articles was performed by pairs using specific assessment scales, Critical Appraisal Skills Program (CASP) adapted for CASP Spain. Then we extracted data on efficacy and safety according to the treatment line assessed. Results We identified 277 references. Finally, nine clinical trials and a meta-analysis complied with inclusion criteria. In first-line induction, treatment with pemetrexed associated with a platinum was similar in terms of efficacy to other alternative chemotherapy regimens, except in patients with non-squamous histology, in whom survival was higher in the experimental group. In maintenance treatment, greater efficacy was seen with pemetrexed in patients with non-squamous histology. In second-line treatment, there were no significant differences in terms of efficacy and safety for pemetrexed treatment versus other chemotherapy options. The most frequent adverse reactions were: hematological, gastrointestinal and neurological. All were significantly less frequent with pemetrexed versus other alternative therapies, except for liver toxicity. Conclusions Due to the high degree of uncertainty as to its efficacy in certain subgroups of patients, including conflicting data; to its recent incorporation, and therefore lack of safety data in the medium and long term, and the high budgetary impact of its incorporation into health systems, it seems reasonable to optimize its use, identifying those patients who may benefit most.
- Open Access
- 1 May 2013
- Published by Elsevier in Medicina Intensiva (English Edition)
- Vol. 37 (4) , 259-283
2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla
- 1 May 2013
- Published by Elsevier in Medicina Intensiva (English Edition)
- Vol. 37 (4) , 259-283
Open Access2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla
- Open Access
- 1 May 2013
- Published by Elsevier in Revista Española de Anestesiología y Reanimación
- Vol. 60 (5) , 263.e1-263.e25
2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla
- 1 May 2013
- Published by Elsevier in Revista Española de Anestesiología y Reanimación
- Vol. 60 (5) , 263.e1-263.e25
Open Access2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla
- 26 February 2013
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 38 (2) , 121-130
Biological treatments for moderate-to-severe psoriasis: indirect comparison
What is known and Objective Psoriasis is a chronic skin disease for which there is an increasing range of treatment options. Biological agents (ustekinumab, adalimumab, infliximab and etanercept) are indicated for moderate‐to‐severe plaque‐type psoriasis in adults who fail to respond to, have a contraindication to, or are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA Unfortunately, with new drugs, the pivotal trials leading to their licensing are often placebo‐controlled trials rather than comparative trials vs. established therapies. Therefore, inference on comparative effectiveness of the newer agents must be derived indirectly, through estimation of effects of the new agents vs. a common comparator. The objective of this study is to compare the relative efficacy of the biological agents through a systematic review of the indirect clinical trial evidence. Methods A systematic literature search was performed for clinical trials of biological agents in psoriasis. Pivotal, randomized, double‐blind, controlled (placebo) trials using intention‐to‐treat analysis were selected for detailed analysis. Trials must include PASI 75 as a primary end point. The indirect comparison was performed using the method of Bucher adjusted with the ITC calculator (Indirect Treatment Comparisons of the Canadian Agency for Drugs and Technologies in Health), etanercept being the reference drug. We defined delta value for therapeutic equivalence as a difference in the efficacy of 25% among the different treatment options. Results and Discussion Fourteen studies (four for ustekinumab, three for adalimumab, three for infliximab and four for etanercept) were included. The indirect comparison results reveal that ustekinumab, adalimumab and infliximab were statistically superior to etanercept with an absolute risk difference for PASI 75 of 12% (95% CI = 5·9–18%), 11% (95% CI = 5·3–16·7%) and 24% (29·7–18·3%) respectively. However, in all situations, the 95% confidence interval does not achieve clinical relevance as no delta exceeds the previously set value (25%). What is new and Conclusion Ustekinumab, adalimumab, infliximab and etanercept can be regarded as clinical equivalents for the treatment of psoriasis. Choice between these agents therefore depends on their relative safety profiles, individual contra‐indications and cost effectiveness.
- 26 February 2013
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 38 (2) , 121-130
Biological treatments for moderate-to-severe psoriasis: indirect comparison
What is known and Objective Psoriasis is a chronic skin disease for which there is an increasing range of treatment options. Biological agents (ustekinumab, adalimumab, infliximab and etanercept) are indicated for moderate‐to‐severe plaque‐type psoriasis in adults who fail to respond to, have a contraindication to, or are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA Unfortunately, with new drugs, the pivotal trials leading to their licensing are often placebo‐controlled trials rather than comparative trials vs. established therapies. Therefore, inference on comparative effectiveness of the newer agents must be derived indirectly, through estimation of effects of the new agents vs. a common comparator. The objective of this study is to compare the relative efficacy of the biological agents through a systematic review of the indirect clinical trial evidence. Methods A systematic literature search was performed for clinical trials of biological agents in psoriasis. Pivotal, randomized, double‐blind, controlled (placebo) trials using intention‐to‐treat analysis were selected for detailed analysis. Trials must include PASI 75 as a primary end point. The indirect comparison was performed using the method of Bucher adjusted with the ITC calculator (Indirect Treatment Comparisons of the Canadian Agency for Drugs and Technologies in Health), etanercept being the reference drug. We defined delta value for therapeutic equivalence as a difference in the efficacy of 25% among the different treatment options. Results and Discussion Fourteen studies (four for ustekinumab, three for adalimumab, three for infliximab and four for etanercept) were included. The indirect comparison results reveal that ustekinumab, adalimumab and infliximab were statistically superior to etanercept with an absolute risk difference for PASI 75 of 12% (95% CI = 5·9–18%), 11% (95% CI = 5·3–16·7%) and 24% (29·7–18·3%) respectively. However, in all situations, the 95% confidence interval does not achieve clinical relevance as no delta exceeds the previously set value (25%). What is new and Conclusion Ustekinumab, adalimumab, infliximab and etanercept can be regarded as clinical equivalents for the treatment of psoriasis. Choice between these agents therefore depends on their relative safety profiles, individual contra‐indications and cost effectiveness.
- 1 January 2013
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 28 (1) , 12-18
Autorización de usos de medicamentos fuera de indicación en un hospital de tercer nivel
- 1 January 2013
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 28 (1) , 12-18
Autorización de usos de medicamentos fuera de indicación en un hospital de tercer nivel
- 31 August 2011
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 26 (4) , 269-270
Los sistemas de alertas como método de detección de errores de medicación
- 31 August 2011
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 26 (4) , 269-270
Los sistemas de alertas como método de detección de errores de medicación
- Open Access
- 1 March 2010
- Published by Elsevier in Farmacia Hospitalaria
- Vol. 34 (2) , 76-84
Análisis del proceso de selección de nuevos medicamentos en un hospital terciario. Años 2004–07
- 1 March 2010
- Published by Elsevier in Farmacia Hospitalaria
- Vol. 34 (2) , 76-84
Open AccessAnálisis del proceso de selección de nuevos medicamentos en un hospital terciario. Años 2004–07
- 1 December 1988
- Vol. 43 (12) , 877-8
Antimicrobial activity of 5-(2-thiophenylidene)-2-thiobarbituric acid.
- 1 December 1988
- Vol. 43 (12) , 877-8
Antimicrobial activity of 5-(2-thiophenylidene)-2-thiobarbituric acid.